Other genetic variants are also involved, such as TM6SF2 (associated with hepatic steatosis and cirrhosis in patients with NAFLD and ALD), the membrane bound O-acyltransferase domain-containing 7 (MBOAT7) (progression of NAFLD and ALD), and other variants related to the genes involved in insulin resistance, lipid metabolism, glucose metabolism, oxidative stress, inflammatory pathways, and fibrosis playing as disease modifiers in patients with NAFLD and ALD. This evidence concerns the gene MBOAT7 and Cirrhosis.